Ryvu Therapeutics SA Net Assets
Ryvu Therapeutics SA net assets. Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has net assets worth zł41.33 Million PLN (≈ $11.37 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł200.96 Million ≈ $55.31 Million USD) and total liabilities (zł159.63 Million ≈ $43.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Ryvu Therapeutics SA annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł41.33 Million |
| % of Total Assets | 20.56% |
| Annual Growth Rate | 29.28% |
| 5-Year Change | -58.24% |
| 10-Year Change | 26.99% |
| Growth Volatility | 196.95 |
Net Assets of Ryvu Therapeutics SA (2010–2025)
Net assets of Ryvu Therapeutics SA from 2010 to 2025. This chart illustrates how Ryvu Therapeutics SA's net assets have evolved over time, based on quarterly financial data. See RVU equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Ryvu Therapeutics SA (2010–2025)
The table below shows the annual net assets of Ryvu Therapeutics SA from 2010 to 2025. For live market cap and overall valuation, see market value of Ryvu Therapeutics SA.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | zł70.75 Million ≈ $19.47 Million |
-50.83% |
| 2024-12-31 | zł143.88 Million ≈ $39.60 Million |
-44.57% |
| 2023-12-31 | zł259.59 Million ≈ $71.44 Million |
-24.40% |
| 2022-12-31 | zł343.39 Million ≈ $94.51 Million |
+102.68% |
| 2021-12-31 | zł169.42 Million ≈ $46.63 Million |
-24.27% |
| 2020-12-31 | zł223.72 Million ≈ $61.57 Million |
+86.81% |
| 2019-12-31 | zł119.76 Million ≈ $32.96 Million |
-38.54% |
| 2018-12-31 | zł194.86 Million ≈ $53.63 Million |
+204.49% |
| 2017-12-31 | zł64.00 Million ≈ $17.61 Million |
+14.87% |
| 2016-12-31 | zł55.71 Million ≈ $15.33 Million |
+18.84% |
| 2015-12-31 | zł46.88 Million ≈ $12.90 Million |
+406.61% |
| 2014-12-31 | zł9.25 Million ≈ $2.55 Million |
+195.78% |
| 2013-12-31 | zł3.13 Million ≈ $861.02K |
-43.45% |
| 2012-12-31 | zł5.53 Million ≈ $1.52 Million |
-51.73% |
| 2011-12-31 | zł11.46 Million ≈ $3.15 Million |
+662.89% |
| 2010-12-31 | zł1.50 Million ≈ $413.48K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ryvu Therapeutics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20995894994.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Ryvu Therapeutics SA Net Assets Breakdown (December 2025)
Ryvu Therapeutics SA net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł9.25 Million | 17.18% |
| Other Comprehensive Income | zł-262.49 Million | -487.59% |
| Other Components | zł519.75 Million | 965.46% |
| Total Equity | zł53.83 Million | 100.00% |
Ryvu Therapeutics SA Competitors by Market Cap
The table below lists competitors of Ryvu Therapeutics SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Minerva Neurosciences Inc
NASDAQ:NERV
|
$108.09 Million |
|
Schloss Wachenheim AG
F:SWA
|
$108.11 Million |
|
CVC Income & Growth Limited
LSE:CVCE
|
$108.14 Million |
|
Taegu Broadcasting Corporation
KQ:033830
|
$108.21 Million |
|
Thuan Duc JSC
VN:TDP
|
$108.01 Million |
|
AS HARJU ELEKTER EO 063
F:HD8
|
$107.96 Million |
|
Excel Cell Electronic Co Ltd
TW:2483
|
$107.96 Million |
|
Asefa Public Company Limited
BK:ASEFA
|
$107.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ryvu Therapeutics SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 143,884,000 to 53,834,000, a change of -90,050,000 (-62.6%).
- Net loss of 101,229,000 reduced equity.
- Other comprehensive income increased equity by 11,179,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-101.23 Million | -188.04% |
| Other Comprehensive Income | zł11.18 Million | +20.77% |
| Other Changes | zł-1.00 | -0.0% |
| Total Change | zł- | -62.59% |
Book Value vs Market Value Analysis
This analysis compares Ryvu Therapeutics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 118.26x to 7.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | zł0.14 | zł16.98 | x |
| 2011-12-31 | zł1.10 | zł16.98 | x |
| 2012-12-31 | zł0.53 | zł16.98 | x |
| 2013-12-31 | zł0.30 | zł16.98 | x |
| 2014-12-31 | zł0.88 | zł16.98 | x |
| 2015-12-31 | zł3.56 | zł16.98 | x |
| 2016-12-31 | zł4.03 | zł16.98 | x |
| 2017-12-31 | zł4.52 | zł16.98 | x |
| 2018-12-31 | zł12.36 | zł16.98 | x |
| 2019-12-31 | zł7.50 | zł16.98 | x |
| 2020-12-31 | zł13.34 | zł16.98 | x |
| 2021-12-31 | zł8.79 | zł16.98 | x |
| 2022-12-31 | zł18.73 | zł16.98 | x |
| 2023-12-31 | zł11.34 | zł16.98 | x |
| 2024-12-31 | zł6.22 | zł16.98 | x |
| 2025-12-31 | zł2.33 | zł16.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ryvu Therapeutics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -188.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -162.61%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 4.17x
- Recent ROE (-188.04%) is below the historical average (-43.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -131.36% | -22.31% | 0.86x | 6.84x | zł-2.12 Million |
| 2011 | -38.73% | -49.22% | 0.52x | 1.53x | zł-5.58 Million |
| 2012 | -116.19% | -68.24% | 0.61x | 2.77x | zł-6.98 Million |
| 2013 | -76.24% | -18.14% | 0.73x | 5.75x | zł-2.70 Million |
| 2014 | 63.22% | 20.27% | 1.08x | 2.90x | zł4.92 Million |
| 2015 | 13.50% | 15.28% | 0.63x | 1.40x | zł1.62 Million |
| 2016 | 4.91% | 5.65% | 0.54x | 1.61x | zł-2.82 Million |
| 2017 | 10.28% | 7.30% | 0.85x | 1.66x | zł177.14K |
| 2018 | -0.06% | -0.14% | 0.30x | 1.33x | zł-19.30 Million |
| 2019 | -30.06% | -84.57% | 0.23x | 1.53x | zł-47.97 Million |
| 2020 | -14.16% | -205.57% | 0.05x | 1.32x | zł-54.06 Million |
| 2021 | -49.02% | -706.91% | 0.05x | 1.42x | zł-95.21 Million |
| 2022 | -24.40% | -215.91% | 0.08x | 1.38x | zł-118.12 Million |
| 2023 | -35.48% | -196.57% | 0.12x | 1.55x | zł-118.07 Million |
| 2024 | -77.45% | -142.92% | 0.21x | 2.63x | zł-125.82 Million |
| 2025 | -188.04% | -162.61% | 0.28x | 4.17x | zł-106.61 Million |
Industry Comparison
This section compares Ryvu Therapeutics SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $200,193,669
- Average return on equity (ROE) among peers: -11.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ryvu Therapeutics SA (RVU) | zł41.33 Million | -131.36% | 3.86x | $108.04 Million |
| Bioton S.A. (BIO) | $1.34 Billion | 2.83% | 0.43x | $80.35 Million |
| Captor Therapeutics S.A. (CTX) | $96.32 Million | -37.26% | 0.17x | $80.35 Million |
| Mabion S.A. (MAB) | $111.44 Million | -5.68% | 0.43x | $35.14 Million |
| Molecure S.A. (MOC) | $81.89 Million | -4.61% | 0.05x | $32.77 Million |
| Nanogroup SA (NNG) | $7.78 Million | -10.77% | 1.47x | $20.80 Million |
| Pharmena S.A. (PHR) | $13.08 Million | -31.23% | 0.29x | $9.07 Million |
| PolTREG S.A. (PTG) | $101.04 Million | -1.95% | 0.22x | $27.34 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $39.49 Million | -33.10% | 0.20x | $4.61 Million |
| Synthaverse S.A. (SVE) | $14.06 Million | 18.07% | 4.23x | $55.05 Million |
About Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myel… Read more